BioSpace News Archive

Independence Blue Cross (Independence) and Children’s Hospital of Philadelphia (CHOP) have signed a new long-term agreement. The agreement, which will be effective July 1, 2020 , represents a shared goal of improving community health care for children and collaborating on quality of care in ways that will benefit children living i

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company met with Health Canada in a Pre-Clinical Trial Application (“Pre-CTA”) meeting to evaluate the potential of a clinical study of Bucillamine in the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 inf

Tracking the spread of the coronavirus is an ongoing challenge. But researchers at Johns Hopkins University are conducting a study that uses an app to collect information that can help localize potential COVID – 19 clusters and flare-ups.

Dr. Elizabeth O’Day will lead personalized medicine investment and adoption efforts globally during three-year term.

Collaboration will continue animal testing of self-assembling vaccine in the treatment of Human Papilloma Virus induced malignancy and Ovarian cancer The company closed the Series-A Preferred financing round of $3.5 million [09-June-2020] NEW YORK , June 9, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announced today that it has entered into a Sponsored

Treatment with LEAF-1401 exposes the tumor to 20-times more pentaglutamated pemetrexed than conventional pemetrexed. Polyglutamated pemetrexed has been shown to be 80-times more potent than pemetrexed in inhibiting thymidylate synthase (TS), a key enzyme in the folate pathway . Pemetrexed (Alimta ® ) is today one of the leading backbone chemotherapies for lung cancer in the wo

Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDA’s Clearance of the IND for BT051, and initiation of a Phase 1 Clinical Trial with patient dosing expected in the coming months.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the closing of the acquisition of the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company.

Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today announced the voting results from its Annual General and Special Meeting of Shareholders (“AGM”) held virtually on June 8, 2020.

AtmosAir Solutions, has announced that its patented bi-polar ionization HVAC device has tested more than 99.9 percent effective in neutralizing coronavirus.